T-E PHARMA

T-E PHARMA is at the forefront of biotechnology, dedicated to developing innovative drugs with both targeting (T) and effector (E) functions, enhancing efficacy and safety in pharmaceutical treatments. T-E PHARMA Holding oversees its subsidiaries, Immunwork, Inc. and T-E Meds, Inc., each playing a critical role in advancing therapeutic solutions. Immunwork, Inc. focuses on research, development, and commercialization of therapeutics based on the proprietary “T-ETM pharmaceuticals” platform, while T-E Meds, Inc. specializes in antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs).

T-E PHARMA is committed to pioneering ultra-long-acting peptide therapeutics and advanced pharmaceutical modalities through its innovative drug-design platform. With leading clinical assets like TE-8214, targeting neuroendocrine tumors and acromegaly, and TE-8105, aimed at treating obesity, type 2 diabetes, and fatty liver disease, T-E PHARMA is making significant strides in addressing critical health challenges. Both candidates have shown excellent tolerability, and Phase II trials are actively being prepared. The company’s headquarters are located in Taipei, TW.

T-E PHARMA is dedicated to excellence in creating homogeneous ADCs/ARCs with high drug-to-antibody ratio (DAR), excellent yield, high purity, and flexible payload incorporation, thanks to its proprietary bioconjugation platform. With a robust pipeline of preclinical candidates targeting various cancers and IND filings planned, T-E PHARMA is poised for continued growth and impact in the pharmaceutical industry. We invite the management of T-E PHARMA to create a customized and exclusive company showcase and product listing on our platform to further enhance their commercial development.